## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:

James H. HELLER et al

Confirmation No. 5202

Serial No. 10/522,013 : Art Unit: 1609

Filed: January 21, 2005 : Examiner: Sznaidman, M.

For: CHOLINERGIC THERAPY FOR : Atty Docket: 000250.00029

INDIVIDUALS WITH LEARNING DISABILITIES

## RESPONSE TO RESTRICTION REQUIREMENT and AMENDMENT

Commissioner of Patents U.S. Patent and Trademark Office Customer Service Window Randolph Building 401 Dulany Street Alexandria, VA 22314

Sir:

In response to the Restriction Requirement mailed July 31, 2007, applicant elects claim Group I. For the species requirements applicants elect cholinesterase inhibitors and donepezil. However, applicant would rather not choose among the species offered for the genetic abnormality of the subject. Applicant has amended the claims which were directed to genetic abnormalities. These claims now recite various learning disabilities.

Applicants request a five-month extension of time until January 31, 2007. Please charge our Deposit Account No. 19-0733 accordingly.